GEO series

WTAP stability enhanced by USP7 promotes enzalutamide resistance in prostate cancer via activating AKT signaling

GSE301437 Homo sapiens (human) RNA-seq (gene expression) 2 samples Submitted 2026/05/15 Platform GPL24676

At a glance

RNA-seq (gene expression) · human · 2 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Topic: Prostate cancerThis series is part of our curated briefing on it.
Samples: 2 samples
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m(6)A-modificationCancer gene therapy · 2026

Summary (written by the submitters)

Castration-resistant prostate cancer (CRPC) is one of the most prevalent cancers in men. The new generation androgen receptor (AR) inhibitor enzalutamide can improve therapeutic effectiveness of patients with CRPC. However, these patients eventually develop to acquired enzalutamide resistance (ENZR), and the mechanisms underlying resistance is not well understood.

Read the full summary ↓

Wilms’ tumor 1-associating protein (WTAP) plays an important role in m6A modification and has been reported as an oncogene in various cancers. Here, we utilized a tissue microarray and collected tissues from prostate cancer (PCa) patients to detect WTAP expression, and found that WTAP is upregulated in PCa. Meanwhile, WTAP over-expression promotes cell proliferation and accelerates tumor growth through colony formation assays and establishing subcutaneous xenograft model in vivo. These findings establish the tumor promoter role of WTAP in prostatic tumorigenesis. Furthermore, we verified that WTAP is a novel responsive gene of AR via promoter activity and chromatin immunoprecipitation (ChIP) assays. Importantly, we uncovered WTAP is upregulated in ENZR cells and WTAP knockdown inhibited the proliferation of ENZR cells. Mechanistically, ubiquitin-speciﬁc protease (USP7) enhanced the stability of WTAP by ubiquitin-proteasome pathway in ENZR cells, thereby WTAP increase promotes AKT signaling through m6A mediated way and AKT inhibitor can abolished the pro-resistance phenotype mediated by WTAP. Together, these findings suggest that WTAP plays a key role in ENZR development of PCa cells and WTAP may be a potential treatment target for ENZR tumors.

Published in

WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m(6)A-modification

Shi R, Gu K, Li H et al. · Cancer gene therapy 2026 · PMID 41981278 · doi:10.1038/s41417-026-01013-y

This dataset

Open GSE301437 in finder → Find more human RNA-seq datasets → Prostate cancer landscape →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE301437_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1285172 and SRA study SRP597122. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41981278) ↗

Samples in this study

The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.

+ 2 more — browse all 2 samples with per-sample file links →

More Prostate cancer datasets

GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing
GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing
GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing
GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing
GSE289619 IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non–small cell lung cancer II 32 samples shares akt, resistance
GSE316535 POFUT1 Serves as an Independent Prognostic Factor and Therapeutic Target by Activating the PI3K/AKT Pathway in Glioma 14 samples shares akt, activating

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.